Recursion Pharmaceuticals, Inc. (RXRX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 3 | 10 | 40 | 44 | 59 | 75 | 55 | 41 |
| Operating profit | $m | -648 | -544 | ||||||
| Net profit | $m | -87 | -186 | -239 | -328 | -464 | -645 | -519 | -409 |
| EPS reported | $ | -1.44 | -1.04 | ||||||
| Operating cashflow per share | $ | -0.83 | -0.66 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -0.85 | -0.67 | ||||||
| Free cash flow | $m | -378 | -354 | ||||||
| Net debt | $m | -725 | -536 | ||||||
| Book value equity | $m | 1,131 | 915 | ||||||
| Book value per share | $ | 2.53 | 1.72 | ||||||
| Number of shares | m | 447.45 | 532.46 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.62 | 2.00 | ||||||
| P/S LTM | x | 24.50 | 33.36 | ||||||
| P/FCF LTM | x | -4.84 | -5.17 | ||||||
| EV/EBITDA LTM | x | -2.08 | -2.62 | ||||||
| EV/Sales LTM | x | 15.60 | 21.41 | ||||||
| Earnings Yield LTM | % | -35.23% | -30.84% | ||||||
| FCF Yield | % | -20.67% | -19.36% | ||||||
| Quality | |||||||||
| ROE | % | -57.01% | -50.41% | ||||||
| ROIC | % | -48.06% | -48.34% | ||||||
| Operating margin | % | -8.68% | -9.92% | ||||||
| Gross margin | % | -61.96% | -46.66% | ||||||
| FCF/Sales | % | -506.52% | -645.82% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +26.92% | -6.77% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -4.85 | -5.72 | ||||||
| Net Debt/EBITDA | x | 1.19 | 1.09 | ||||||
| EBIT/Net interest | x | -358.08 | -364.62 | ||||||
| Net debt/market cap | % | +1.02% | 0.00% | ||||||
| Net debt/Equity | x | -0.64 | -0.59 | ||||||
| Gross debt/equity | x | 0.07 | 0.07 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Recursion Pharmaceuticals, Inc. (RXRX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free